Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
2024's Driving Clearing Robots: Master Suggestions and Surveys - 25 Food varieties to Remember for Your Eating regimen for Ideal Wellbeing
- 3Saturn shines with the waxing moon at sunset on Nov. 29
- 4A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
- 5Flying without a Real ID? That'll soon cost you $45, TSA says.
- Death toll from floods in Afghanistan rises to 61
- Investigating Remarkable Espresso Flavors: Upgrade Your Day to day Blend
- Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique
- Really focusing on Succulents: Tips and Procedures
- The Main 10 Natural life Protection Associations
- First Phosphate advances battery-grade phosphate project as analysts highlight strategic Federal support
- Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024
- NASA set to launch Artemis 2 moon mission today, the 1st crewed lunar flight since 1972
- Make your choice for a definitive Christmas place to get-away!
